Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P J Pockros

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
Archives of Internal Medicine|February 25, 1999
Mastocytosis: diverse presentations and outcomesJ D Pauls, J Brems, P J Pockros, et al.
Journal of Viral Hepatitis|March 1, 1996
Fluctuations in viral load (HCV RNA) are relatively insignificant in untreated patients with chronic HCV infectionT T Nguyen, A Sedghi-Vaziri, L B Wilkes, et al.
Alimentary Pharmacology & Therapeutics|August 29, 2013
Hepatitis C virus therapy is associated with lower health care costs not only in noncirrhotic patients but also in patients with end-stage liver diseaseS C Gordon, F M Hamzeh, P J Pockros, et al.
Alimentary Pharmacology & Therapeutics|January 23, 2008
Histological benefits of virological response to peginterferon alfa-2a monotherapy in patients with hepatitis C and advanced fibrosis or compensated cirrhosisG T Everson, L Balart, S S Lee, et al.
Journal of Viral Hepatitis|September 29, 1998
Relationship between biochemical and virological responses to interferon therapy in chronic hepatitis C infection. Consensus Interferon Study GroupP J Pockros, M Tong, W M Lee, et al.
Hepatology (Baltimore, Md.)|February 15, 2001
Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis CK R Reddy, T L Wright, P J Pockros, et al.
Hepatology (Baltimore, Md.)|September 26, 1997
Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study GroupM J Tong, K R Reddy, W M Lee, et al.
Alimentary Pharmacology & Therapeutics|October 30, 2016
All-oral direct-acting antiviral therapy in HCV-advanced liver disease is effective in real-world practice: observations through HCV-TARGET databaseK R Reddy, J K Lim, A Kuo, et al.
Journal of Viral Hepatitis|July 2, 2013
Long-term clearance of hepatitis C virus following interferon α-2b or peginterferon α-2b, alone or in combination with ribavirinM P Manns, P J Pockros, G Norkrans, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Archives of Internal Medicine|February 25, 1999
Mastocytosis: diverse presentations and outcomesJ D Pauls, J Brems, P J Pockros, et al.
Journal of Viral Hepatitis|March 1, 1996
Fluctuations in viral load (HCV RNA) are relatively insignificant in untreated patients with chronic HCV infectionT T Nguyen, A Sedghi-Vaziri, L B Wilkes, et al.
Alimentary Pharmacology & Therapeutics|August 29, 2013
Hepatitis C virus therapy is associated with lower health care costs not only in noncirrhotic patients but also in patients with end-stage liver diseaseS C Gordon, F M Hamzeh, P J Pockros, et al.
Alimentary Pharmacology & Therapeutics|January 23, 2008
Histological benefits of virological response to peginterferon alfa-2a monotherapy in patients with hepatitis C and advanced fibrosis or compensated cirrhosisG T Everson, L Balart, S S Lee, et al.
Journal of Viral Hepatitis|September 29, 1998
Relationship between biochemical and virological responses to interferon therapy in chronic hepatitis C infection. Consensus Interferon Study GroupP J Pockros, M Tong, W M Lee, et al.
Hepatology (Baltimore, Md.)|February 15, 2001
Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis CK R Reddy, T L Wright, P J Pockros, et al.
Hepatology (Baltimore, Md.)|September 26, 1997
Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study GroupM J Tong, K R Reddy, W M Lee, et al.
Alimentary Pharmacology & Therapeutics|October 30, 2016
All-oral direct-acting antiviral therapy in HCV-advanced liver disease is effective in real-world practice: observations through HCV-TARGET databaseK R Reddy, J K Lim, A Kuo, et al.
Journal of Viral Hepatitis|July 2, 2013
Long-term clearance of hepatitis C virus following interferon α-2b or peginterferon α-2b, alone or in combination with ribavirinM P Manns, P J Pockros, G Norkrans, et al.
Pageof 3